tool name

close
tool goes here

FDA approves anticlotting drug that targets strokes

The Food and Drug Administration said Friday that it approved an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It’s a potential blockbuster in a new category of medicines to prevent strokes.

Published: Dec. 29, 2012 at 12:05 a.m. PST
0 comments

The Food and Drug Administration said Friday that it approved an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It’s a potential blockbuster in a new category of medicines to prevent strokes.

The agency previously rejected the drug twice, most recently in June, awaiting additional data from company trials. The FDA cleared the pill for treating the most common type of irregular heartbeat, atrial fibrillation, in patients at risk for strokes or dangerous clots.

The FDA said it approved the drug based on an 18,000-patient study conducted by the drugmakers.

News Tribune news services

JOIN THE DISCUSSION | Register here

We welcome comments. Please keep them civil, short and to the point. ALL CAPS, spam, obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. Thanks for taking part — and abiding by these simple rules. A thorough explanation of rules of conduct can be found in our Terms of Service. If you have any questions, including why your comment may not be showing immediately after you submit it, be sure to visit the commenting FAQ.

CONTESTS

Similar stories

  • FDA warns about another round of fake cancer drug

    The Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year.

  • Weight loss drug Belviq gets overdue US launch

    Arena Pharmaceuticals says its weight loss drug Belviq will be available to U.S. patients beginning next week, nearly a year after the drug was officially approved by federal regulators.

  • FDA warns about unapproved Botox

    Federal regulators have warned more than 350 medical practices that Botox they may have received from a Canadian supplier is unapproved and could be counterfeit or unsafe.

  • Feds, peanut butter plant reach agreement

    Federal officials and the eastern New Mexico peanut butter plant that was shuttered after a salmonella outbreak have reached an agreement that will allow the plant to reopen.

  • FDA will investigate added caffeine in foods

    WASHINGTON — For people seeking an energy boost, companies are increasing their offerings of foods with added caffeine. A new caffeinated gum may have gone too far.